Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada

ConclusionRomosozumab/alendronate was associated with reduced costs and greater benefit relative to other comparators. Probabilistic, deterministic, and scenario analyses indicate that romosozumab/alendronate represents the best value for money; the uncertainty analyses are robust, and therefore romosozumab should be considered for reimbursement by public drug plans in Canada .
Source: Archives of Orthopaedic and Trauma Surgery - Category: Orthopaedics Source Type: research